Literature DB >> 10858357

Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital.

C Chanal1, R Bonnet, C De Champs, D Sirot, R Labia, J Sirot.   

Abstract

beta-Lactam resistance was studied in 1,072 consecutive P. mirabilis clinical strains isolated at the Clermont-Ferrand teaching hospital between April 1996 and March 1998. The frequency of amoxicillin resistance was 48.5%. Among the 520 amoxicillin-resistant isolates, three resistance phenotypes were detected: penicillinase (407 strains [78.3%]), extended-spectrum beta-lactamase (74 strains [14. 2%]), and inhibitor resistance (39 strains [7.5%]). The penicillinase phenotype isolates were divided into three groups according to the level of resistance to beta-lactams, which was shown to be related to the strength of the promoter. The characterization of the different beta-lactamases showed that amoxicillin resistance in P. mirabilis was almost always (97%) associated with TEM or TEM-derived beta-lactamases, most of which evolved via TEM-2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858357      PMCID: PMC89988          DOI: 10.1128/AAC.44.7.1930-1935.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

2.  Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum beta-lactamase TEM-9 (RHH-1) of Klebsiella pneumoniae.

Authors:  C Mabilat; S Goussard; W Sougakoff; R C Spencer; P Courvalin
Journal:  Plasmid       Date:  1990-01       Impact factor: 3.466

3.  Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia.

Authors:  D Y Wu; L Ugozzoli; B K Pal; R B Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Characterization of the beta-lactamase promoter of pBR322.

Authors:  D R Russell; G N Bennett
Journal:  Nucleic Acids Res       Date:  1981-06-11       Impact factor: 16.971

Review 5.  Compilation and analysis of Escherichia coli promoter DNA sequences.

Authors:  D K Hawley; W R McClure
Journal:  Nucleic Acids Res       Date:  1983-04-25       Impact factor: 16.971

6.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

Review 7.  Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

Authors:  J Sirot; C Chanal; A Petit; D Sirot; R Labia; G Gerbaud
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

8.  Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids.

Authors:  C M Chanal; D L Sirot; A Petit; R Labia; A Morand; J L Sirot; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

9.  Convergent evolution of TEM-26, a beta-lactamase with extended-spectrum activity.

Authors:  L C Hibbert-Rogers; J Heritage; N Todd; P M Hawkey
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

10.  Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France.

Authors:  D L Sirot; F W Goldstein; C J Soussy; A L Courtieu; M O Husson; J Lemozy; M Meyran; C Morel; R Perez; C Quentin-Noury
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  16 in total

1.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2002-03       Impact factor: 4.562

3.  Experimental prediction of the natural evolution of antibiotic resistance.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2003-04       Impact factor: 4.562

4.  Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period.

Authors:  Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Chromosome-encoded AmpC and CTX-M extended-spectrum β-lactamases in clinical isolates of Proteus mirabilis from Korea.

Authors:  Wonkeun Song; Juwon Kim; Il Kwon Bae; Seok Hoon Jeong; Young Hee Seo; Jong Hee Shin; Sook Jin Jang; Young Uh; Jeong Hwan Shin; Mi-Kyung Lee; Kyungwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Characterization of CTX-M-140, a Variant of CTX-M-14 Extended-Spectrum β-Lactamase with Decreased Cephalosporin Hydrolytic Activity, from Cephalosporin-Resistant Proteus mirabilis.

Authors:  Guo-Bao Tian; Yi-Qi Jiang; Ying-Min Huang; Yun Qin; Lian-Qiang Feng; Xue-Fei Zhang; Hong-Yu Li; Lan-Lan Zhong; Kun-Jiao Zeng; Sandip Patil; Yong Xing; Xi Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes.

Authors:  K Cohen-Nahum; L Saidel-Odes; K Riesenberg; F Schlaeffer; A Borer
Journal:  Infection       Date:  2009-12-07       Impact factor: 3.553

Review 8.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type beta-lactamase.

Authors:  Noriyuki Nagano; Naohiro Shibata; Yuko Saitou; Yukiko Nagano; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  Integration of a transposon Tn1-encoded inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome.

Authors:  Thierry Naas; Marie Zerbib; Delphine Girlich; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.